Targeting α5β1 integrin for imaging of tumor angiogenesis and antiangiogenic therapy (A10)

• Subject Area: Nuclear Medicine, Radiotherapy, Radiobiology
• Term: from 2017 to 2021
• Project identifier: Deutsche Forschungsgemeinschaft (DFG) - Project number 68647618

Although the transmembrane receptor αvβ3 integrin has been considered a specific cellular marker for angiogenic activity for decades, recent data suggest that the α5β1 integrin might be more suitable for this purpose. This project aims to exploit the potential of α5β1 integrin as a target for novel imaging probes and antiangiogenic radiotherapeutics, and to elucidate interplay and correlation of α5β1 integrin expression with that of other angiogenesis markers, such as αvβ3 integrin or the oncofetal slice variant of fibronectin, extradomain B.

• DFG Programme: Collaborative Research Centres
• Subproject of: SFB 824: Imaging for Selection, Monitoring and Individualisation of Cancer Therapies
• Applicant Institution: Technische Universität München (TUM)
• Project Head: Privatdozent Dr. Johannes Notni